Vaccines worries hit GSK
Published: 19:59 28 Oct 2026 AEDT
Drugs giant GSK PLC (LSE:GSK, NYSE:GSK) has slipped despite beating forecasts, with investors focused on falling vaccine sales and a guarded profit outlook
GSK shares fell 4% to 1,852p in early trading, after the FTSE 100 drugmaker's third-quarter results beat expectations on sales and core earnings.
Sales of £8.9 billion were in line with the consensus forecast, according to Jefferies, which compiled the figures using Visible Alpha data.
Core operating profit of £3.1 billion was 5% ahead, helped by a better gross margin and lower selling and administration costs.
Core earnings per share of 54.6p beat the consensus figure of 50.3p by 9%, with a lower tax rate also helping.
The weak spot was vaccines, where sales of £2.58 billion missed forecasts of £2.61 billion.
GSK reaffirmed its 2026 guidance, but core earnings per share growth is still expected only in the lower half of its 7% to 9% range.
That is despite royalty income now being expected at the top of its range, at about £900 million, and lower interest charges of £700 million to £750 million, down from £800 million.
Jefferies said consensus sits about 50 basis points below the midpoint of the implied range. The broker rates the shares at "buy" with a price target of 2,500p.